Pair Name	Dihydroberberine, Sunitinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Proliferation
Gene Regulation	Up-regulation	Expression	CCNB1	hsa891
	Up-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CCNE1	hsa898
	Up-regulation	Expression	CDK1	hsa983
	Down-regulation	Expression	COX2	hsa4513
	Down-regulation	Expression	IKBKE	hsa9641
	Down-regulation	Expression	IL1B	hsa3553
	Down-regulation	Phosphorylation	MAPK14	hsa1432
	Down-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Phosphorylation	NFKB1	hsa4790
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H460	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0459
	NCI-H1299	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0060
In Vivo Model	Four to six‐week‐old non‐obese diabetic severe combined immunodeficiency (NOD/SCID) mice were injected subcutaneously into the right flank with 4×10⁶ NCI‐H460 cells suspended in sterile physiological saline.
Result	DCS induced the expression of cell cycle signal molecules that are known to be affected by JNK and p38. The change of cell cycle, in turn, led to down-regulation of JNK and p38, and further reduced IL-1 secretion. Collectively, these findings highlight potential molecular mechanisms of DCS chemotherapeutic activity and suggest that DCS is an efficacious strategy in NSCLC therapy.